Quote of the Day

“The challenge that [new]anti-obesity medications have is one of legacy. The products that have been available in the past haven’t been all that dramatic or effective in weight loss and that sort of stuck in the mind, I believe, of prescribers. So the new products [Belviq and Qsymia] are going to have to demonstrate efficacy before they’re going to get widespread use.” — Craig Oberg, R.Ph., a managing consultant with The Burchfield Group, told AIS’s Drug Benefit News.